Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis

Chi Wen Lo, Wei Ming Li, Hung Lung Ke, Yi Huei Chang, Hsi Chin Wu, I. Hsuan Alan Chen, Jen Tai Lin, Chao Yuan Huang, Chung Hsin Chen, Jen Shu Tseng, Wun Rong Lin, Yuan Hong Jiang, Yu Khun Lee, Chung You Tsai, Shiu Dong Chung, Thomas Y. Hsueh, Allen W. Chiu, Yeong Chin Jou, Ian Seng Cheong, Yung Tai ChenJih Sheng Chen, Bing Juin Chiang, Chih Chin Yu, Wei Yu Lin, Chia Chang Wu, Chuan Shu Chen, Han Yu Weng, Yao Chou Tsai

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)


Background: The advantage of adjuvant chemotherapy for upper urinary tract urothelial cancer (UTUC) has been reported, whereas its impact on upper tract cancer with variant histology remains unclear. We aimed to answer the abovementioned question with our real-world data. Design, Setting, and Participants: Patients who underwent radical nephroureterectomy (RNU) and were confirmed to have variant UTUC were retrospectively evaluated for eligibility of analysis. In the Taiwan UTUC Collaboration database, we identified 245 patients with variant UTUC among 3,109 patients with UTUC who underwent RNU after excluding patients with missing clinicopathological information. Intervention: Those patients with variant UTUC were grouped based on their history of receiving adjuvant chemotherapy or not. Outcome Measurements and Statistical Analysis: Propensity score matching was used to reduce the treatment assignment bias. Multivariable Cox regression model was used for the analysis of overall, cancer-specific, and disease-free survival. Results and Limitations: For the patients with variant UTUC who underwent adjuvant chemotherapy compared with those without chemotherapy, survival benefit was identified in overall survival in univariate analysis (hazard ratio (HR), 0.527; 95% confidence interval (CI), 0.285–0.973; p = 0.041). In addition, in multivariate analysis, patients with adjuvant chemotherapy demonstrated significant survival benefits in cancer-specific survival (OS; HR, 0.454; CI, 0.208–0.988; p = 0.047), and disease-free survival (DFS; HR, 0.324; 95% CI, 0.155–0.677; (p = 0.003). The main limitations of the current study were its retrospective design and limited case number. Conclusions: Adjuvant chemotherapy following RNU significantly improved cancer-related survivals in patients with UTUC with variant histology.
期刊Frontiers in Oncology
出版狀態已發佈 - 4月 2022

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究


深入研究「Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis」主題。共同形成了獨特的指紋。